Bavencio (Avelumab)

Brand Name

Bavencio

Generic Name

Avelumab

View Brand Information

FDA approval date: March 23, 2017

Classification: Programmed Death Ligand-1 Blocker

Form: Injection

What is Bavencio (Avelumab)?

BAVENCIO is a programmed death ligand-1 blocking antibody indicated for: Merkel Cell Carcinoma Adults and pediatric patients 12 years and older with metastatic MCC.

Approved To Treat

Top Global Experts

Save this treatment for later

Not sure about your diagnosis?

Check Your Symptoms

Related Clinical Trials

A Phase 1/2, First-in-Human, Open Label, Dose Escalation and Expansion Study of AU-007, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-2Rα Binding, in Patients With Unresectable Locally Advanced or Metastatic Cancer

Who is this study for: Patients with Advanced Solid Tumor, Metastatic Cancer

Enrollment Status: Recruiting

Publish Date: October 15, 2025

Intervention Type: Drug

Study Drugs: AU-007, Aldesleukin

Study Phase: Phase 1/Phase 2

Summary: This is a first in human, open-label, multi-center Phase 1 / 2 study to evaluate the safety, tolerability, and initial efficacy of AU-007 in patients with advanced solid tumors. AU-007 will be administered either as a monotherapy, or in combination with a single loading dose of aldesleukin, or with both AU-007 and aldesleukin given every 2 weeks (Q2w). Once the recommended phase 2 dose (RP2D) of A...

A Phase I/II Study of M3814 and Avelumab in Combination With Hypofractionated Radiation in Patients With Advanced/Metastatic Solid Tumors and Hepatobiliary Malignancies

Who is this study for: Adult patients with Metastatic or Locally Advanced Unresectable Solid Tumor or Cholangiocarcinoma or Gallbladder Carcinoma

Enrollment Status: Recruiting

Publish Date: October 10, 2025

Intervention Type: Drug, Radiation, Procedure

Study Drugs: Avelumab, Peposertib

Study Phase: Phase 1/Phase 2

Summary: This phase I/II trial studies the best dose and side effects of peposertib and to see how well it works with avelumab and hypofractionated radiation therapy in treating patients with solid tumors and hepatobiliary malignancies that have spread to other places in the body (advanced/metastatic). Peposertib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Imm...

Phase 1/2 Modular Dose Escalation With Cohort Expansion of CP-506 (HAP) in Patients With Solid Tumor Types With High Incidence of HRD/FAD in Monotherapy or With Carboplatin or Patients With Solid Tumour and OPD Receiving ICI

Who is this study for: Patients with Solid Tumor

Enrollment Status: Recruiting

Publish Date: October 07, 2025

Intervention Type: Drug

Study Drugs: CP-506, Carboplatin, Immune Checkpoint Inhibitor

Study Phase: Phase 1/Phase 2

Summary: A modular, first time in human, open label, multiple dose, accelerated escalation with cohort expansion study of the safety and pharmacokinetics of intravenous infusion of CP-506, a tumor agnostic Hypoxia Activated Prodrug in patients with HRD/FAD solid tumours or tumor types with high incidence of HRD/FAD in monotherapy or in combination with carboplatin or patients with solid tumour and oligopro...

View All Clinical Trials

Related Latest Advances

Avelumab maintenance in patients with metastatic urothelial carcinoma in a real-life expanded-access program.

Journal: Future oncology (London, England)

Published: October 17, 2025

Immune checkpoint inhibitor-induced nephrotic syndrome: a pharmacovigilance analysis of 404 FAERS cases and literature case series.

Journal: Renal failure

Published: October 14, 2025

Progressive Decrease in Interleukin 6 Levels After Successive Doses of Avelumab in a Rapid Drug Desensitization Protocol.

Journal: Journal of investigational allergology & clinical immunology

Published: October 08, 2025

View All Latest Advances

Brand Information

BAVENCIO (avelumab)

1DOSAGE FORMS AND STRENGTHS

Injection: 200 mg/10 mL (20 mg/mL), clear, colorless to slightly yellow solution in a single-dose vial.

2CONTRAINDICATIONS

None.

3ADVERSE REACTIONS

The following clinically significant adverse reactions are described elsewhere in the labeling:

Severe and fatal immune-mediated adverse reactions
Infusion-related reactions
Complications of allogeneic HSCT
Major adverse cardiovascular events

3.1Clinical Trials Experience

Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.

The data described in the WARNINGS AND PRECAUTIONS section reflect exposure to BAVENCIO 10 mg/kg intravenously every 2 weeks as a single agent in 1854 patients enrolled in the JAVELIN Merkel 200 and JAVELIN Solid Tumor trials and to BAVENCIO 10 mg/kg intravenously every 2 weeks in combination with axitinib 5 mg orally twice daily in 489 patients enrolled in the JAVELIN Renal 100 and JAVELIN Renal 101 trials. In the BAVENCIO monotherapy population, 25% of patients were exposed for ≥ 6 months and 9% were exposed for ≥ 12 months. The population characteristics of BAVENCIO in combination with axitinib are shown below. When BAVENCIO was used in combination with axitinib, 70% of patients were exposed for ≥ 6 months and 31% were exposed for ≥ 12 months. The following criteria were used to classify an adverse reaction as immune-mediated: onset within 90 days after last dose of BAVENCIO, no spontaneous resolution within 7 days of onset, treatment with corticosteroids or other immunosuppressant or hormone replacement therapy, biopsy consistent with immune-mediated reaction, and no other clear etiology.

3.2Postmarketing Experience

The following adverse reactions have been identified during postapproval use of BAVENCIO. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.

Blood and lymphatic system disorders: neutropenia

Hepatobiliary disorders: sclerosing cholangitis

4DESCRIPTION

Avelumab is a programmed death ligand1 (PD-L1) blocking antibody. Avelumab is a human IgG1 lambda monoclonal antibody produced in Chinese hamster ovary cells and has a molecular weight of approximately 147 kDa.

BAVENCIO (avelumab) Injection for intravenous use is a sterile, preservative-free, non-pyrogenic, clear, colorless to slightly yellow solution. Each single-dose vial contains 200 mg avelumab in 10 mL (20 mg/mL). Each mL contains 20 mg avelumab, D-mannitol (51 mg), glacial acetic acid (0.6 mg), polysorbate 20 (0.5 mg), sodium hydroxide (0.3 mg), and Water for Injection. The pH range of the solution is 5.0 – 5.6.

5HOW SUPPLIED/STORAGE AND HANDLING

BAVENCIO (avelumab) Injection is a sterile, preservative-free, and clear, colorless to slightly yellow solution for intravenous infusion supplied as a single-dose vial of 200 mg/10 mL (20 mg/mL), individually packed into a carton (NDC 44087-3535-1).

6PATIENT COUNSELING INFORMATION

Advise the patient to read the FDA-approved patient labeling (Medication Guide).

7PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton

NDC 44087-3535-1

BAVENCIO

200 mg/10 mL

For intravenous infusion

Dispense the enclosed

1 vial

Rx only

EMD

PRINCIPAL DISPLAY PANEL - 10 mL Vial Carton